Brief Introduction

Established in 1996, Amoytop Biotech is the first biopharmaceutical company in Fujian listed on SSE STAR Market (Sci-tech innovation board, Shanghai Stock Exchange). The company is specialized in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing mainly on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to providing better solutions for major diseases, including viral hepatitis, malignant tumors and immunotherapy. Up to now, Amoytop Biotech has established national post-doctoral workstation and national-local joint research center, which are awarded as National Innovative Enterprise and National Intellectual Property Advantage Enterprise.

Company Overview

Full name Xiamen Amoytop Biotech Co., Ltd.
Abbreviations AMOYTOP
Code 688278
Founded 1996-8-7
Listing 2020-1-17
Domicile Xiamen
Website http://www.amoytop.com
Email ir@amoytop.com
STAR Theme Biomedicine
CSRCSector Pharmaceutical Manufacturing(C27)
Has weighted voting rights structure? No

Financials

Highlights

  2019 2018 2017
Earnings Per Share 0.18 0.04 0.01
R&D expenditure as a % of operating revenue 8.87% 9.67% 13.61%
Operating Revenue 729,666,393.33 448,282,685.52 323,081,460.29
Net Income 64,293,940.53 16,002,935.32 5,168,602.99

Income Statement (Unit: RMB mn)

  2019 2018 2017
Operating Revenue 729.67 448.28 323.08
Operating Costs 79.97 55.94 41.68
Operating Income 116.07 34.72 10.05
Pretax Income 91.01 14.27 7.67
Income Tax 26.72 -1.73 2.50
Net Income 64.29 16.00 5.17

Balance Sheet(Unit: RMB mn)

  2019 2018 2017
Assets
Current Assets-Total 445.20 373.85 295.38
Non-current Assets-Total 344.63 333.92 341.75
Total Assets 789.83 707.77 637.12
Liabilities
Current Liabilities-Total 150.72 130.04 118.57
Non-current Liabilities-Total 75.55 78.47 35.30
Total Liabilities 226.27 208.51 153.86
Stockholder's Equity
Share Capital 473.39 473.39 473.39
Retained Profits 90.16 25.87 9.87
Total Owners' Equity 563.55 499.26 483.26

Cash Flow Statement (Unit: RMB mn)

  2019 2018 2017
Net Cash Flows-Operating 123.30 89.15 -11.41
Net Cash Flows-Investing -44.73 -14.55 -26.89
Net Cash Flows-Financing -17.86 -13.76 -12.29

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
杨英 138.08 38.32%
通化东宝 122.29 33.94%
孙黎 32.54 9.03%
郑善贤 11.82 3.28%
蔡智华 11.43 3.17%
赖伏英 9.97 2.77%
左仲鸿 6.66 1.85%
李一奎 5.74 1.59%
王君业 3.83 1.06%
兰春 1.56 0.43%
31 Dec 2019

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.